BioSpace News Archive

Tefen – New Licensed Cannabis Producer in Israel Concludes $23 Million Local Sales Deal

Countries Around the World Seek to Import Israeli Cannabis Products but Cannot Due to Israel Government Bureaucracy Preventing Approval: “The Israeli Export Window is Closing.”

July 9, 2018
·
3 min read
Pharm Country

Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon® Patch

Mylan N.V. today announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis’ Exelon® Patch.

July 9, 2018
·
4 min read
Business

Pace Analytical Announces National Center for Testing and Innovation

Pace Analytical Services, LLC, has announced that it is changing the name of its subsidiary, ESC Lab Sciences, to the Pace Analytical National Center for Testing & Innovation.

July 9, 2018
·
2 min read
FDA

Oculocare’s Alleye® Receives FDA 510(k) Clearance for Monitoring Eyesight in AMD

Oculocare medical Inc. announces today the FDA 510(k) clearance of Alleye(R), a mobile medical software application indicated for the detection and monitoring of age-related macular degeneration (AMD).

July 9, 2018
·
2 min read
Pharm Country

Adult-use Sales to Re-accelerate the Cannabis Market

Data published by Ameri Research Inc., indicates that the global legal cannabis market was valued at USD 14.3 Billion in 2016 and is expected to reach a value of USD 63.5 Billion by 2024

July 9, 2018
·
10 min read
Business

HedgePath Pharmaceuticals Closes Second Tranche of Mayne Pharma Financing

Additional $1.6 million in preferred stock and warrant funding to support SUBA BCCNS regulatory program

July 9, 2018
·
5 min read
FDA

FDA Grants Eagle Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)

Eagle Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted seven years of orphan drug exclusivity (ODE) in the U.S., for BENDEKA™ (bendamustine hydrochloride injection, or bendamustine HCI)

July 9, 2018
·
3 min read
Deals

Bovie Medical Corporation Announces Agreement to Sell “Core” Business Segment to Symmetry Surgical, Inc. for Total Cash Consideration of $97 million

Divestiture and Sale of the Core business segment represents an important strategic transaction that significantly enhances Bovie Medical’s balance sheet and allows the Company to further focus on the commercialization of J-Plasma/Renuvion™ Cosmetic Technology

July 9, 2018
·
8 min read
Deals

Health Enterprise Partners Raises $188 Million in Oversubscribed Third Fund

HEP III will invest in next generation of healthcare information technology and services companies

July 9, 2018
·
4 min read
Drug Development

Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994

Clinical data demonstrate SPR994 to be well tolerated at single and multiple ascending doses

July 9, 2018
·
8 min read